Cancer Drug Development Forum (CDDF) multi-Stakeholder workshop on Impact of the Microbiome on Cancer Growth and Therapy is organized by Cancer Drug Development Forum (CDDF) and will be held from Feb 15 - 16, 2019 at Right of the Isar Hospital, Munich, Bavaria, Germany.
The target audience for this medical event is a multi-disciplinary community of researchers, medical oncologists, nutritionists and other healthcare professionals, representatives from pharmaceutical, nutrition and biomedical industries, patient advocates, and students who have a keen interest in microbiome research.
The CDDF multi-stakeholder workshop on Impact of the Microbiome on Cancer Growth and Therapy is organized by the Cancer Drug Development Forum (CDDF) in cooperation with the Munich Tumour Centre (TZM), with the aim of enhancing the understanding of the human microbiome and its critical role in cancer growth and treatment. The workshop provides comprehensive insights into the human microbiome and its application to cancer research as well as valuable opportunities to establish network in the emerging microbiome field.
The first edition of this workshop will be held on 15/16 February 2019 in Munich, Germany and will offer small group lectures and interactive discussions to effectively exchange expertise and broaden perspectives. The lectures will focus on the links between the human microbiome and cancer with a special attention to inflammation and immune system.
During the workshop, participants will enhance their knowledge of the current and future development in the microbiome research and its clinical relevance. Most importantly, delegates will network with various players and experts in the emerging microbiome sector.
Registration Fees (Based on a 1.5-day Workshop)
Additional details will be posted as soon as they are available.
|Registration Type||End Date||Price|
|Academics - Fee||14 Feb,2019||EUR 250.00|
|Industry Representatives - Fee||14 Feb,2019||EUR 1100.00|
|Patient Advocates / Students - Fee||14 Feb,2019||EUR 120.00|
|Representatives from regulatory authorities, policymakers, HTAs - Fee||14 Feb,2019||EUR 150.00|